NicOx Completes Enrollment In Second Pivotal Phase 3 Study For Naproxcinod And Provides Development Update
NicOx S.A. (Eurolist: COX) announced it has successfully completed the enrollment of 1020 patients in the 302 pivotal phase 3 study for naproxcinod, in-line with projections. Naproxcinod is the Company’s lead investigational drug product and the first compound in the COX-Inhibiting Nitric Oxide-Donating (CINOD) class. [click link for full article]
More: continued here
Filed under: Arthritis on December 15th, 2007